Integer (NYSE:ITGR) Hits New 12-Month High – Here’s Why

Integer Holdings Co. (NYSE:ITGR) shares reached a new 52-week high on Tuesday . The stock traded as high as $144.22 and last traded at $143.22, with a volume of 5118 shares trading hands. The stock had previously closed at $141.00.

Wall Street Analysts Forecast Growth

ITGR has been the topic of a number of research reports. Benchmark upped their target price on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Bank of America upped their price objective on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Citigroup increased their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and set a $140.00 target price (up previously from $125.00) on shares of Integer in a research report on Friday, October 25th. Finally, Truist Financial raised their price target on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $145.44.

Integer Trading Down 1.2 %

The business has a 50 day moving average of $136.68 and a 200 day moving average of $129.24. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of 43.63, a PEG ratio of 1.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.27 EPS. As a group, research analysts predict that Integer Holdings Co. will post 5.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. American Century Companies Inc. boosted its holdings in shares of Integer by 249.7% in the second quarter. American Century Companies Inc. now owns 15,710 shares of the medical equipment provider’s stock valued at $1,819,000 after buying an additional 11,218 shares during the period. Hsbc Holdings PLC boosted its position in shares of Integer by 123.3% during the second quarter. Hsbc Holdings PLC now owns 6,458 shares of the medical equipment provider’s stock worth $745,000 after buying an additional 3,566 shares during the period. Public Sector Pension Investment Board grew its holdings in shares of Integer by 7.8% during the second quarter. Public Sector Pension Investment Board now owns 73,672 shares of the medical equipment provider’s stock worth $8,530,000 after buying an additional 5,358 shares in the last quarter. Xponance Inc. raised its position in Integer by 4.9% in the 2nd quarter. Xponance Inc. now owns 2,112 shares of the medical equipment provider’s stock valued at $245,000 after buying an additional 99 shares during the last quarter. Finally, Point72 Europe London LLP bought a new stake in Integer in the 2nd quarter valued at approximately $6,241,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.